Corvus Pharmaceuticals (CRVS)
(Delayed Data from NSDQ)
$4.14 USD
+0.04 (0.98%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $4.13 -0.01 (-0.24%) 6:18 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Income Statements
Fiscal Year end for Corvus Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 23 | 33 | 39 | 44 | 49 |
Income After Depreciation & Amortization | -23 | -33 | -39 | -44 | -49 |
Non-Operating Income | -4 | -9 | -5 | 38 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -27 | -41 | -43 | -6 | -47 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -27 | -41 | -43 | -6 | -47 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -27 | -41 | -43 | -6 | -47 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -24 | -32 | -38 | -43 | -49 |
Depreciation & Amortization (Cash Flow) | -1 | 0 | 1 | 1 | 0 |
Income After Depreciation & Amortization | -23 | -33 | -39 | -44 | -49 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 48.03 | 46.55 | 41.85 | 29.48 | 29.35 |
Diluted EPS Before Non-Recurring Items | -0.56 | -0.89 | -1.03 | -1.47 | -1.59 |
Diluted Net EPS (GAAP) | -0.56 | -0.89 | -1.03 | -0.20 | -1.59 |
Fiscal Year end for Corvus Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 5.93 | 6.26 | 5.65 | 5.57 | 5.62 |
Income After SG&A, R&D, and Dept/Amort Expenses | -5.93 | -6.26 | -5.65 | -5.57 | -5.62 |
Non-Operating Income | 1.67 | 0.55 | -1.00 | -0.44 | -0.88 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -4.26 | -5.70 | -6.65 | -6.00 | -6.50 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -4.26 | -5.70 | -6.65 | -6.00 | -6.50 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -4.26 | -5.70 | -6.65 | -6.00 | -6.50 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 59.71 | 49.04 | 49.04 | 48.97 | 47.50 |
Diluted EPS Before Non-Recurring Items | -0.07 | -0.12 | -0.14 | -0.12 | -0.14 |
Diluted Net EPS (GAAP) | -0.07 | -0.12 | -0.13 | -0.12 | -0.14 |